Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) has reached an agreement with Zhongshen Innovation on the authorization cooperation of the innovative drug BIOS-0629 project.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that the company has reached an exclusive licensing cooperation agreement for the innovative drug BIOS-0629 project in the Greater China region with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. ("Zhongshen Innovation") and signed a "Technology Development Cooperation Agreement" and supplementary agreement. Regarding the R&D progress of the BIOS-0629 project, it is currently in the PCC stage, with its indication being solid tumors. According to the agreement, the company will be responsible for the research and development, clinical trials, and registration of the collaborative product. Zhongshen Innovation will be responsible for the R&D transformation, production, sales, and market expansion in the Greater China region. After the signing of the contract, Zhongshen Innovation will pay a milestone payment of 300 million RMB based on the R&D milestones. The company will also receive a 10% commission on sales revenue of the collaborative product in the Greater China region. The announcement stated that through this cooperation, both parties will leverage their respective resources and technological advantages in the field of innovative drug R&D, deepen collaborative innovation, accelerate the transformation of the BIOS-0629 project from laboratory results to clinical applications, and jointly promote innovative achievements.